Physiological and Functional Properties of Probiotics
GENERAL TERMS AND CONDITIONS FOR USING THIS ELECTRONIC PUBLICATION

Introduction
Use of the material provided in this publication is subject to the Terms and Conditions in this document. These Terms and Conditions are designed to make it clear to users of this material what they may and may not do with the content provided to them. Our aim has been to make the Terms and Conditions unambiguous and fair to all parties, but if further explanation is required, please send an e-mail to info@fil-idf.org with your question.

Permitted Use
The User may make unlimited use of the Content, including searching, displaying, viewing on-screen and printing for the purposes of research, teaching or private study but not for commercial use.

Copyright
Site layout, design, images, programs, text and other information (collectively, the “Content”) is the property of the International Dairy Federation and is protected by copyright and other intellectual property laws. Users may not copy, display, distribute, modify, publish, reproduce, store, transmit, create derivative works from, or sell or license all or any part of the content obtained from this publication. Copyright notices must not be modified or removed from any Content obtained under the terms of this licence.

Any questions about whether a particular use is authorized and any requests for permission to publish, reproduce, distribute, display or make derivative works from any Content should be directed to info@fil-idf.org

Availability
Although the International Dairy Federation publications are developed in view of maximum user-friendliness, the International Dairy Federation cannot guarantee any of these products to work on or with any particular computer system.

Liability
Although the International Dairy Federation has taken reasonable care to ensure that the information, data and other material made available in its publication is error-free and up-to-date, it accepts no responsibility for corruption to the information, data and other material thereafter, including but not limited to any defects caused by the transmission or processing of the information, data and other material. The information made available in this publication, has been obtained from or is based upon sources believed by the International Dairy Federation to be reliable but is not guaranteed as to accuracy or completeness. The information is supplied without obligation and on the understanding that any person who acts upon it or otherwise changes his/her position in reliance thereon does so entirely at his/her own risk.

Send any comments or inquiries to:
International Dairy Federation (I.N.P.A.)
Diamant Building
Boulevard Auguste Reyers 80
1030 Brussels
Belgium
Phone: +32 2 733 98 88
Fax: +32 2 733 04 13
E-mail: info@fil-idf.org
Web: www.fil-idf.org

VIEW THE UPCOMING IDF EVENTS AT: http://www.fil-idf.org/EventsCalendar.htm
Physiological and Functional Properties of Probiotics

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>1</td>
</tr>
<tr>
<td>Physiological and Functional Properties of Probiotics</td>
<td>2</td>
</tr>
<tr>
<td>A. Mercenier, I. Lenoir-Wijnkoop, M.E. Sanders</td>
<td></td>
</tr>
<tr>
<td>1. Introduction</td>
<td>2</td>
</tr>
<tr>
<td>2. Project group activities and conclusions</td>
<td>2</td>
</tr>
<tr>
<td>3. Recommendations</td>
<td>4</td>
</tr>
<tr>
<td>3.1. Establishing probiotic properties of strains</td>
<td>4</td>
</tr>
<tr>
<td>3.2. Good Practice Guidelines</td>
<td>4</td>
</tr>
<tr>
<td>4. Conclusion</td>
<td>5</td>
</tr>
<tr>
<td>References</td>
<td>6</td>
</tr>
</tbody>
</table>
Physiological and Functional Properties of Probiotics

Foreword

This issue of the Bulletin comprises the summary and conclusions of the work carried out by a project group under the Joint IDF/ISO Action Team on Probiotics, operating under the IDF Standing Committee on Microbiological Methods of Analysis. The group was initiated to provide input into on-going international debates on methods to determine probiotic functionality, and undertook to determine which in vitro, animal or human assessments of physiological function should be recommended to determine that a microbial strain meets the minimum criteria for being considered a probiotic.

The IDF is grateful to the group, and particularly to the authors of the summary, A. Mercenier (CH), I. Lenoir-Wijnkoop (FR) and M.E. Sanders (US), as well as to A. Constable (CH) for providing this valuable insight into the potential and limits of determining probiotic functionality that will hopefully help to progress the work carried out by the International Life Sciences Institute (ILSI) and other entities.

Christian Robert
Director General

May 2008
Physiological and Functional Properties of Probiotics

A. Mercenier¹, I. Lenoir-Wijnkoop², M.E. Sanders³

1. Introduction

In the last twenty years, major efforts have been invested in the proper identification and selection of probiotic strains. Today, there is widespread agreement that probiotic strains should be safe, effective and stable in the final product. This, however, is a general recommendation and does not define which specific tests should be applied when selecting a new probiotic strain. It is accepted that health claims have to be supported by well-conducted clinical trials using the final product in the targeted population. Before such trials, potential probiotic strains are to be selected from the huge natural reservoir of candidates. Most of the screening is usually performed using a variety of in vitro assays and animal models. However, the field lacks substantiated correlation between the results of historical methods used to select probiotic strains and clinical manifestations in humans. This situation reflects our limited knowledge of the mechanisms underlying the purported health benefits of probiotics, which renders the design of validated screening assays particularly challenging. The situation is further complicated by the fact that probiotics are intended to impact a wide array of human ecosystems (oral, stomach, small intestine, colon, vaginal tract) and a quite diverse range of physiological functions. Moreover, the interplay between the different partners of a given ecosystem is very complex and still poorly understood.

2. Project group activities and conclusions

The purpose of the project group (comprised of the experts listed in Table 1) was to determine which in vitro, animal or human assessments of physiological function should be recommended to determine that a microbial strain meets the minimum criteria for being considered a probiotic. The intent was to agree upon a list of physiological and functional properties required of probiotic bacteria and to establish methods to assess these functions. This effort was expected to build on the general guidelines established in 2002 by the Joint FAO/WHO working group on Drafting Guidelines for the Evaluation of Probiotics in Food (http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf). The project group arrived at the following conclusions:

(1) The potential scope of physiological activities of probiotics is so broad that no unique test or battery of tests could be defined that would be considered essential to all probiotics or probiotic applications.

For example, although in vitro tests such as bile and acid resistance are commonly performed, results from these tests would not be necessarily relevant to a probiotic that was targeted for certain sites, such as the oral cavity [1].

As another example, adhesion to epithelial cells is often cited in the literature as an important selection criterion for probiotic strains. The underlying idea is that bacteria need to be in close contact with the epithelial barrier to exert their beneficial effect. This is a narrow and perhaps incorrect view of the in vivo situation with probiotics. For example, bacterial soluble molecules (metabolites, cell wall components, and DNA) are known to mediate some signaling to the host (for a review, see [2]). In addition, most in vitro settings used to study adhesion do not account for the complex and changing mucus lining found along the human gastro-intestinal tract. It

¹ Dr. Annick Mercenier, Head of Allergy Nutrition & Health Department, Nestlé Research Center Vers-Chez-Les-Blanc, CH-1000 Lausanne, E-mail: annick.mercenier@rdls.nestle.com
² Mrs. Irene Lenoir-Wijnkoop, Director Expert Scientific Affairs Danone Research, Route Départementale 128 F-91767 PALAISEAU Cédex, E-mail: irene.lenoir@danone.com
³ Dr. Mary Ellen Sanders, Consultant, Dairy & Food Culture Technologies, 7119 S. Glencoe Ct., Centennial, CO 80122 USA, E-mail: mes@mesanders.com
has also been shown that these assays are very hard to standardize and control and that results may vary substantially from one laboratory to another [3].

(2) **There is no solid documentation that strains, which perform well in physiological tests perform any better in human evaluations than strains which perform poorly in these tests.**

Even for simple tests such as acid or bile resistance, there are currently no agreed cut off points for what would constitute “good” vs. “poor” performance in these tests, and no systematic comparison of *in vitro* results with human functionality have been conducted. In short, there is no solid documentation that strains, which perform well in these tests, perform any better in human evaluations than strains which perform poorly in these tests. Under these circumstances, there is no basis for requiring these tests be conducted for all probiotics. Nevertheless, they might still be used as part of a thorough characterization of the candidate probiotic strain. Moreover, it cannot be excluded that in the future, when supported by a systematic correlation to *in vivo* biological effects, *in vitro* tests may help classify strains into “functional groups”. As it stands at present, it should be made very clear though that they are neither sufficient nor necessarily indicative of a “probiotic status”.

(3) **Establishing Standard Operating Procedures for limited numbers of functional assays is premature considering the current status of research.**

A large number of *in vitro* assays and animal models attempting to mimic - at least in part - the human situation are presently in use or under development. This reflects the complexity and variety of:

i. ecological niches targeted for probiotic administration;

ii. action site and mediation of effects;

iii. targeted health benefits;

iv. target populations; and

v. impact of the final probiotic formulation/product on functional effects.

The knowledge of the mechanisms underlying the cross-talk between the probiotic strain and the host is currently limited (although the field is rapidly moving), which makes the selection of any one particular assay difficult to support. In addition, validated biomarkers or surrogate markers that can be followed to substantiate specific effects in humans are still under development.

The PASSCLAIM EU network and ILSI Task Forces [4]; [5]; [6] have recently reviewed a variety of assays used to study the effects of probiotics on the host, with a special focus on the impact probiotics may have on the host immune system. Their recommendations certainly represent a move forward. Along the same line, the PROSAFE EU network evaluated the relevance of specific *in vitro* and *in vivo* assays to evaluate the safety of probiotic and dairy strains [7].

(4) **Concerning health claims, it is recommended today to conduct two independent double-blind placebo-controlled clinical trials with the final probiotic product in the targeted population.**

Establishing efficacy in humans requires studies in humans. Existing worldwide regulatory guidelines on the level and type of information needed vary on this subject [8], and in some locations such as the European Union recommendations are still under discussion. From a scientific perspective, clinical trials or human intervention studies should follow the principles of “good clinical practice”. This includes a study population with sufficient numbers of individuals to reach statistical power/significance. Such criteria will likely be required by regulatory agencies for support of health claims in the future anyway ([http://eur-lex.europa.eu/LexUriServ/site/en/gj/2007/l_012/l_01220070118en00030018.pdf](http://eur-lex.europa.eu/LexUriServ/site/en/gj/2007/l_012/l_01220070118en00030018.pdf)).
Table 1. Participants in the project group on Physiological and Functional Properties of Probiotics of the IDF/ISO Joint Action Team on Probiotics

<table>
<thead>
<tr>
<th>Name (Country)</th>
<th>Name (Country)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B Bianchi Salvadori (IT)</td>
<td>S Blum Sperisen (CH)</td>
</tr>
<tr>
<td>P Breeuwer (CH)</td>
<td>E Brockmann (DK)</td>
</tr>
<tr>
<td>C Cavadini (CH)</td>
<td></td>
</tr>
<tr>
<td>M Danielsen (DK)</td>
<td>B Degeest (BE)</td>
</tr>
<tr>
<td>F Dellaglio (IT)</td>
<td>D Ellekaer (DK)</td>
</tr>
<tr>
<td>J Foy (US)</td>
<td></td>
</tr>
<tr>
<td>M Gueimonde (FI)</td>
<td>KJ Heller (DE)</td>
</tr>
<tr>
<td>G Huys (BE)</td>
<td>BL Jacobsen (DK)</td>
</tr>
<tr>
<td>I Lenoir-Wijnkoop (FR)</td>
<td></td>
</tr>
<tr>
<td>R Lodi (IT)</td>
<td>A Mercenier (CH)</td>
</tr>
<tr>
<td>V Ninane (BE)</td>
<td>M Pineiro (IT)</td>
</tr>
<tr>
<td>T Sako (JP)</td>
<td></td>
</tr>
<tr>
<td>ME Sanders (US)</td>
<td>J Schrezenmeir (DE)</td>
</tr>
<tr>
<td>A Sepulchre (FR)</td>
<td>C Stanton (IE)</td>
</tr>
<tr>
<td>V Vankerckhoven (BE)</td>
<td></td>
</tr>
</tbody>
</table>

3. Recommendations

3.1 Establishing probiotic properties of strains

With the current state of the science, the best approach to establish probiotic properties of a candidate strain would start with defining target human physiological function to be impacted by the probiotic, defining the target populations (e.g., infants, elderly, healthy, at risk), and finally applying the best available methods to study this function. In this process, well-controlled *in vitro* tests would reduce the number of strains to be studied in animal models and so help selecting the best candidate strain to perform clinical trials. One flow diagram for the approach to document physiological functionality for a commercial strain follows:

i. Definition of the targeted health benefit, target population and intended product format.
ii. Identification of most relevant *in vitro* selection tests, usually more than one, in order to select most appropriate candidate strains. The test(s) based on a mechanistic hypothesis may later serve as supporting evidence for the substantiation of the health claim.
iii. Verify technological and organoleptic properties of the strains.
iv. Conduct animal studies; if possible or if relevant, use more than one recognized model.
v. Deposit strain in international strain collection for research purposes, restricting access, if desired, for commercial purposes.
vi. Perform pilot clinical trial in the target population followed by at least one double blind placebo controlled (DBPC) intervention study to support purported health claim.
vii. Build scientific dossier and present dossier to regulatory authorities.
viii. Translate scientific evidence into a claim that is properly understood by the target population.

3.2 Good Practice Guidelines

Whilst it was considered premature under existing knowledge to establish standardized procedures for any one specific physiological or functional test, a series of good practice guidelines could be established. While some of these guidelines might not be applicable for every specific case of use for a probiotic microorganism, they could provide a framework for evaluating the strength of support of physiological function. The working group came up with a number of recommendations concerning microbial aspects that are too often insufficiently taken into account or described in publications (Table 2).
Table 2. Requirements to fulfill when conducting in vitro and in vivo studies with probiotic strains and probiotic containing products.

<table>
<thead>
<tr>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Work with properly identified strains.</td>
</tr>
<tr>
<td>Specify the correct name and number of the strain and from what source it was isolated.</td>
</tr>
<tr>
<td>Check purity of the strain and when relevant precisely describe probiotic mixes/ combinations (identification and relative counts of the individual strains).</td>
</tr>
<tr>
<td>Proper assessment of safety based on the characteristics of the genus, species and strain, intended use and target consumer of any microbe newly proposed as a probiotic must be conducted. One component of this assessment is determination of the potential risk of transferability of phenotypic antibiotic resistances observed for the strain.</td>
</tr>
<tr>
<td>Describe growth conditions and growth phase at which strains were collected as well as final counts/dose administered in the study.</td>
</tr>
<tr>
<td>Standardize these conditions when comparing strains to each other.</td>
</tr>
<tr>
<td>Specify conditions of the probiotic preparation or post-harvesting treatments (e.g., washes, freezing, buffer).</td>
</tr>
<tr>
<td>Use reference strains (or reference compounds) that should ideally be included in successive tests when the assays show high technical variability.</td>
</tr>
<tr>
<td>Determine degree of strain-specificity of effects by including additional (number depending on the complexity of the assay) strains in the assay.</td>
</tr>
<tr>
<td>Run dose-response curves.</td>
</tr>
<tr>
<td>Include appropriate controls (e.g. to eliminate effect of acidification by the strains).</td>
</tr>
<tr>
<td>Perform statistical analysis of the results and ensure statistical power and significance.</td>
</tr>
</tbody>
</table>

4. Conclusion

The development of standard criteria for probiotic selection is difficult due to the diversity of microbes used as probiotics, the range of conceivable physiological endpoints, the different mechanisms that may operate to achieve an overall result and different possible end users. The colonized environments of the human body remain incompletely described. Additionally, characteristics of the cross-talk between a probiotic strain and the intestinal microbiota and the host, which takes place into a dynamic and complex ecological niche, must be elucidated. However, the use of well-controlled in vitro and in vivo assays is important for selecting the best candidate strain for a specific intended use, being aware that the ultimate proof of health promoting effects will come from human intervention trials. In the course of pre-clinical studies, the physiological properties of a candidate strain should be investigated in-depth and should be well-documented. This information will enable a thorough characterization of the strain and could be helpful support for obtaining approval of ethical committees when preparing clinical trials, and when building the scientific dossier necessary to support health claims. Preliminary recommendations concerning the process and practice of establishing the probiotic properties of a strain are provided. Unraveling the mechanisms, identifying relevant biomarkers, standardizing microbial methods and investing efforts to establish a correlation between in vitro and in vivo assays, and human trials, will all help this field to progress. To this end, the IDF work programme was carried forward to the ILSI Europe Task Force and Expert Group on Probiotics that are currently preparing guidance for assessing probiotic beneficial effects, which will be reviewed in a scientific workshop before publication in a peer-reviewed journal.
References


PHYSIOLOGICAL AND FUNCTIONAL PROPERTIES OF PROBIOTICS

ABSTRACT

Summary and conclusions of the work of an IDF project group to establish a list of physiological and functions properties required of probiotic bacteria and to establish methods to assess these functions.

Keywords: bacteria, functional properties, health, probiotic

6 pp - English only

INTERNATIONAL DAIRY FEDERATION

INSTRUCTIONS TO AUTHORS

Submission of papers
Submission of a manuscript (whether in the framework of an IDF subject on the programme of work or an IDF event) implies that it is not being considered contemporaneously for publication elsewhere. Submission of a multi-authored paper implies the consent of all authors.

Types of contribution
Monographs; separate chapters of monographs; review articles; technical and or scientific papers presented at IDF events; communications; reports on subjects on the IDF programme of work.

Language
All papers should be written in English.

Manuscripts
- Files to be sent electronically on CD-ROM, diskette or by e-mail.
- Final document in Word 2000 or later.
- All tables/figures included in final document to be sent also in separate Word, Excel or PowerPoint files, in colour format. Pictures to be sent in tif or eps format (resolution 300 DPI).
- All files to be named with author's surname plus title of paper/tables/figures.

References
- References in the document to be numbered and placed between square brackets.
- Reference lists at the end of the document to contain the following:
  - Names and initials of all authors;
  - Title of paper (or chapter, if the publication is a book);
  - If the publication is a journal, title of journal (abbreviated according to 'Bibliographic Guide for Editors and Authors', published by the American Chemical Society, Washington, DC), and volume number, and page numbers; for example: 1 Singh, H. & Creamer, L.K. Aggregation & dissociation of milk protein complexes in heated reconstituted skim milks. J. Food Sci. 56:238-246 (1991).
  - If the publication is a book, names of the publishers, city or town, and the names and initials of the editors;
  - If the publication is a thesis, name of the university and city or town;
  - Page number or number of pages, and date.


Abstracts
An abstract not exceeding 150 words must be provided for each paper/chapter to be published.

Address
Authors & co-authors must indicate their full address (including e-mail address).

Conventions on spelling and editing
IDF's conventions on spelling and editing should be observed. See Annex 1.

ANNEX 1 IDF CONVENTIONS ON SPELLING AND EDITING

In the case of native English speakers the author's national conventions (British, American etc.) are respected for spelling, grammar etc. but errors will be corrected and explanation given where confusion might arise, for example, in the case of units with differing values (gallon) or words with significantly different meanings (billion).

* Usually double quotes and not single quotes
? Half-space before and after question marks, and exclamation marks ± Half-space before and after
microorganisms Without a hyphen
Infra-red With a hyphen
et al. Not underlined nor italic
e.g., i.e.,... Spelled out in English - for example, that is
litr Not liter unless the author is American
ml, mg,... Space between number and ml, mg,
skimmilk One word if adjective, two words if substantive
sulfuric, sulfite, sulfate Not sulphuric, sulphite, sulphate (as agreed by IUPAC)
AOAC International Not AOAC
programme Not program unless a) author is American or b) computer program
milk and milk product rather than "milk and dairy product" - Normally some latitude can be allowed in non scientific texts
-ize, -ization Not -ise, -isation with a few exceptions
Decimal comma in Standards (only) in both languages (as agreed by ISO)
No space between figure and % - i.e. 6%, etc.
Milkfat One word
USA, UK, GB No stops
Figure To be written out in full
1000-9000 No comma
10 000, etc No comma, but space
hours ° h
second ° s
litre ° l
the Netherlands

Where two or more authors are involved with a text, both names are given on one line, followed by their affiliations, as footnotes for example: A.A. Uthar1 & B. Prof2
1 University of .......
2 Danish Dairy Board ......

IDF does not spell out international organizations